EXPLAINED: 20 - The Real Truth

iPhone 14 Popular In China?, Netflix May Lose Comics, Elon Musk's Starlink Slows, Byron Allen Faces $10B Lawsuit And More Top Financial Media Stories Monday, Sept. 26

Bloomberg

Benzinga · Sep 26, 2022

No, AI won't change Big Pharma

Claims that artificial intelligence will change the way drugs are made are almost certainly overblown. Here’s why

Salon · Sep 24, 2022

Moderna seeks emergency authorization for COVID booster for children

The application for children ages 6 months to under 6 years is expected to be completed later this year.

Axios · Sep 23, 2022

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga · Sep 19, 2022

Check Out What Whales Are Doing With MRNA

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 35 strange trades.

Benzinga · Sep 15, 2022

Take whatever COVID booster you can get, says head of EU drugs watchdog

People in Europe should take whatever COVID-19 booster is available to them in the coming months, Emer Cooke, Executive Director of the European Medicines Agency (EMA), said in a Reuters Next Newsmaker interview ahead of an expected autumn rise in infections.

Reuters · Sep 14, 2022

Top Financial Stories Wednesday, September 14: Multiple Antitrust Setbacks For Google, Bitcoin Crashes, Visa Finds New Gun Control System Ineffective And More…

Reuters

Benzinga · Sep 14, 2022

Is the new omicron vaccine worth it?

The omicron-specific booster vaccine hit the market — some wonder if it's worth getting

Salon · Sep 14, 2022

Commentary: Did the US jump the gun with the new omicron-targeted vaccines?

Last month, the FDA authorized omicron-specific vaccines, accompanied by breathless science-by-press release and a media blitz. Just days after the FDA’s move, the Centers for Disease Control and Prevention followed, recommending updated boosters for anyone age 12 and up who had received at least two doses of the original COVID-19…

Tribune News Service · Sep 14, 2022

Singapore grants interim approval for Moderna's bivalent Covid booster vaccine

SINGAPORE: Singapore on Wednesday granted interim authorisation for a bivalent Covid-19 booster vaccine made by Moderna, the government said in a statement.

Bangkok Post · Sep 14, 2022